These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10705468)

  • 1. Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419.
    Tabuchi S; Ito H; Sogabe H; Kuno M; Kinoshita T; Katumi I; Yamamoto N; Mitsui H; Satoh Y
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):1-15. PubMed ID: 10705468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
    J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
    Castro JL; Ball RG; Broughton HB; Russell MG; Rathbone D; Watt AP; Baker R; Chapman KL; Fletcher AE; Patel S; Smith AJ; Marshall GR; Ryecroft W; Matassa VG
    J Med Chem; 1996 Feb; 39(4):842-9. PubMed ID: 8632408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
    Tabuchi S; Nakanishi I; Satoh Y
    Bioorg Med Chem Lett; 1998 Jun; 8(12):1449-54. PubMed ID: 9873368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
    Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
    Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.
    Harper EA; Griffin EP; Shankley NP; Black JW
    Br J Pharmacol; 1999 Mar; 126(6):1496-503. PubMed ID: 10217545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
    Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
    Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
    Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
    J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of 11C-labeled nonpeptide antagonists for cholecystokinin receptors: [11C]L-365,260 and [11C]L-365,346.
    Haradahira T; Inoue O; Kobayashi K; Suzuki K
    Nucl Med Biol; 1998 Apr; 25(3):203-8. PubMed ID: 9620624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzodiazepine analogues L365,260 and L364,718 as gastrin and pancreatic CCK receptor antagonists.
    Huang SC; Zhang L; Chiang HC; Wank SA; Maton PN; Gardner JD; Jensen RT
    Am J Physiol; 1989 Jul; 257(1 Pt 1):G169-74. PubMed ID: 2473653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.
    Sinha J; Kurup A; Paleti A; Gupta SP
    Bioorg Med Chem; 1999 Jun; 7(6):1127-30. PubMed ID: 10428383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK-480. Synthesis and structure-activity relationships of FK-480 and related compounds.
    Satoh Y; Matsuo T; Sogabe H; Itoh H; Tada T; Kinoshita T; Yoshida K; Takaya T
    Chem Pharm Bull (Tokyo); 1994 Oct; 42(10):2071-83. PubMed ID: 7805132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
    Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
    J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Veber DF; Freidinger RM; Chang RS; Lotti VJ
    J Med Chem; 1988 Jan; 31(1):176-81. PubMed ID: 3336017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological effects of newly synthesized cholecystokinin analogs.
    Verspohl EJ; LaMura M
    Horm Res; 2000; 53(4):177-84. PubMed ID: 11044801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260.
    Lotti VJ; Chang RS
    Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
    Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
    J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New 1,4-benzodiazepin-2-one derivatives as gastrin/cholecystokinin-B antagonists.
    Satoh M; Kondoh Y; Okamoto Y; Nishida A; Miyata K; Ohta M; Mase T; Murase K
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2159-67. PubMed ID: 8582018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.